[Management of hormone deprivation therapies in prostate cancer: Role of the nurse]. / Hormonothérapie dans le cancer de la prostate : quel rôle pour l'IDE en 2020 ?
Prog Urol
; 30(15): 958-963, 2020 Nov.
Article
in Fr
| MEDLINE
| ID: mdl-33109456
Hormone deprivation therapies play a key role in the treatment of prostate cancer. These treatments require standardized care and regular monitoring. The objective of this work was to review the different hormonal therapies available, their side effects and the role of a coordinating nurse in the management of these therapies. First generation hormone therapy is the standard treatment for metastatic prostate cancer. In the past years, second generation hormone therapies have been indicated in combination with first-generation hormone therapies at different stages of the disease. These molecules are responsible for several side effects that should be monitored and prevented. Thus, after an initial assessment, clinical and paraclinical follow-up are essential. Our center has set up monitoring by a coordinating nurse (IDEC) to optimize the education and follow-up of the patient, but also to provide psychosocial support adapted throughout the patient's care path under hormone therapy. This monitoring and information function by IDEC can be facilitated by new digital solutions.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
/
Antineoplastic Agents, Hormonal
/
Nurse's Role
/
Androgen Antagonists
Type of study:
Guideline
Limits:
Humans
/
Male
Language:
Fr
Journal:
Prog Urol
Journal subject:
UROLOGIA
Year:
2020
Type:
Article
Affiliation country:
France